Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 3/20 | 0.31 |
| ▸ | MMP8 | P22894 | 3/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP12 | P39900 | 2/20 | 0.31 |
| ▸ | MMP14 | P50281 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24360745 | 1.00 | TUBB1 (0.51) | TUBB1NOD1FOLH1KIF11ALB | |
| SCHEMBL22309062 | 0.92 | TUBB1 (0.57) | TUBB1MMP1MMP3MMP9MMP8 | |
| SCHEMBL20732182 | 0.92 | TUBB1 (0.57) | TUBB1MMP1MMP3MMP9MMP8 | |
| SCHEMBL20732400 | 0.88 | TUBB1 (0.48) | TUBB1FOLH1 | |
| SCHEMBL24410173 | 0.88 | TUBB1 (0.48) | TUBB1FOLH1 | |
| SCHEMBL24409949 | 0.87 | TUBB1 (0.49) | TUBB1 | |
| SCHEMBL20732390 | 0.87 | TUBB1 (0.49) | TUBB1 | |
| SCHEMBL22316491 | 0.86 | TUBB1 (0.60) | TUBB1FOLH1MMP1MMP3MMP9 | |
| SCHEMBL24575157 | 0.86 | TUBB1 (0.60) | TUBB1FOLH1MMP1MMP3MMP9 | |
| SCHEMBL22316492 | 0.86 | TUBB1 (0.60) | TUBB1FOLH1MMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125941-A1 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125941-A1 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | SHBG, HSD17B7, CYP17A1 | TUBB1 802/4885NOD1 2021/4885FOLH1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.